# Study to Examine the Clinical Efficacy and the Nonsteroidal Anti-inflammatory Drug (NSAID)-Sparing Effect of Secukinumab Over 16 Weeks in Patients With Ankylosing Spondylitis

> **NCT02763046** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 211 (actual)

## Conditions studied

- Ankylosing Spondylitis

## Interventions

- **DRUG:** Secukinumab (AIN457) 150 mg s.c.
- **DRUG:** Secukinumab (AIN457) 150 mg s.c.
- **DRUG:** Placebo - Secukinumab (AIN457) 150 mg s.c.

## Key facts

- **NCT ID:** NCT02763046
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-31
- **Primary completion:** 2019-09-24
- **Final completion:** 2019-09-24
- **Target enrollment:** 211 (ACTUAL)
- **Last updated:** 2021-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02763046

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02763046, "Study to Examine the Clinical Efficacy and the Nonsteroidal Anti-inflammatory Drug (NSAID)-Sparing Effect of Secukinumab Over 16 Weeks in Patients With Ankylosing Spondylitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02763046. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*